MCZ-038

MCZ-038 (18-24 h) potently inhibits the growth of Gram-positive bacteria including MSSA, MRSA, VRSA, and VRE with MIC values of 4-8 µg/mL, and shows no activity against Gram-negative bacteria^[1].
MCZ-038 (0-100 µg/mL) shows moderate cytotoxicity against Vero, NIH-3T3, and HepG2 cells, with selectivity indices ranging from 2 to 10 relative to its antistaphylococcal activity^[1].
MCZ-038 (4-40 µg/mL; 24 h) exhibits concentration-dependent bactericidal activity against S. aureus ATCC 29213, reducing bacterial load by ~4 log₁₀ CFU/mL at 10x MIC (40 µg/mL) over 24 h^[1].
MCZ-038 (0.125-16 µg/mL; 18-24 h) exhibits partial synergy with Gentamicin (HY-A0276) against S. aureus ATCC 29213 (ΣFIC 0.625) and a synergistic bactericidal effect in combination with gentamicin against both S. aureus ATCC 29213 and gentamicin-resistant MDR MRSA NRS119^[1].
MCZ-038 (4 µg/mL; 24-48 h) eradicates pre-formed S. aureus ATCC 29213 biofilms as effectively as vancomycin^[1].
MCZ-038 (4 µg/mL; 24 h) exhibits superior activity against intracellular S. aureus ATCC 29213 in J774A.1 macrophages, reducing bacterial load by ~0.6 log₁₀ CFU/mL at 4 µg/mL over 24 h^[1].
MCZ-038 (2 µg/mL; 30 days) shows no propensity to induce resistance in S. aureus ATCC 29213 over 30 days of serial passaging^[1].
MCZ-038 (0-64 µg/mL; 10 h) exerts its antimicrobial activity by perturbing bacterial membrane integrity and fluidity, without targeting cell wall, DNA, RNA, or protein biosynthesis, and does not cause unspecific membrane disruption^[1].